Iteos Therapeutics Insiders

ITOSDelisted Stock  USD 10.15  0.00  0.00%   
Iteos Therapeutics employs about 173 people. The company is managed by 11 executives with a total tenure of roughly 404 years, averaging almost 36.0 years of service per executive, having 15.73 employees per reported executive. Breaking down Iteos Therapeutics' management performance can provide insight into the firm performance.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

Iteos Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1849) % which means that it has lost $0.1849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3497) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Iteos Therapeutics Workforce Comparison

Iteos Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,438. Iteos Therapeutics holds roughly 173 in number of employees claiming about 7% of equities under Health Care industry.

Iteos Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iteos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iteos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Iteos Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Iteos Therapeutics Notable Stakeholders

An Iteos Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Iteos Therapeutics often face trade-offs trying to please all of them. Iteos Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Iteos Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michel DetheuxCEO PresidentProfile
Phillipe BrantegemVicePresident ResourcesProfile
Matthew GallChief OfficerProfile
Matthew MBAChief OfficerProfile
Ryan BakerHead RelationsProfile
Joanne MDChief OfficerProfile
Adi OsovskyExecutive LegalProfile
Yvonne McGrathChief OfficerProfile
FACP MDInterim OfficerProfile
David MDChief OfficerProfile
Philippe BrantegemExecutive ResourcesProfile

About Iteos Therapeutics Management Performance

The success or failure of an entity such as Iteos Therapeutics often depends on how effective the management is. Iteos Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Iteos management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Iteos management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people.
Please note, the imprecision that can be found in Iteos Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Iteos Therapeutics. Check Iteos Therapeutics' Beneish M Score to see the likelihood of Iteos Therapeutics' management manipulating its earnings.

Iteos Therapeutics Workforce Analysis

Traditionally, organizations such as Iteos Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Iteos Therapeutics within its industry.

Iteos Therapeutics Manpower Efficiency

Return on Iteos Therapeutics Manpower

Revenue Per Employee202.3K
Revenue Per Executive3.2M
Net Loss Per Employee777K
Net Loss Per Executive12.2M
Working Capital Per Employee2.7M
Working Capital Per Executive42.7M
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Consideration for investing in Iteos Stock

If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance